Alteration of plasma von Willebrand factor in the treatment of

- retinal vein occlusion with cystoid macular edema 2
- Short title: Plasma von Willebrand factor in retinal vein occlusion with macular 3
- 4 edema

1

- 5 Hirai¹, Mariko Yamashita², Masanori Matsumoto³, Takevuki Hiromasa
- Nishiyama¹, Daishi Wada¹, Naoko Okabe¹, Yutaro Mizusawa¹, Hironobu Jimura¹, 6
- 7 Tetsuo Ueda¹, Nahoko Ogata^{1*}
- 9 ¹Department of Ophthalmology, Nara Medical University, Kashihara, Japan
- 10 Phone: +81-744-29-8884 (ext.3433), Fax: +81-744-23-8032
- 11 Email: hirai-masa@naramed-u.ac.jp (H.H.), k158380@naramed-u.ac.jp (T.N.),
- 12 d.wada@naramed-u.ac.jp (D.W.), naoko0811@naramed-u.ac.jp (Naoko
- Okabe), urotauyuwasazumi@naramed-u.ac.jp (Y.M.), j-hiro@naramed-u.ac.jp 13
- 14 (H.J.), tueda@naramed-u.ac.jp (U.T.)
- ²Department of Ophthalmology, Nara City Hospital, Nara, Japan 15
- 16 Phone: +81-742-24-1251, Fax: +81-744-22-2478
- 17 Email: marko.yamashita@gmail.com (M.Y.)

- 18 ³Department of Blood Transfusion Medicine, Nara Medical
- University, Kashihara, Japan 19
- 20 Phone: +81-744-22-3051, Fax: +81-744-29-0771
- 21 E-mail: mmatsumo@naramed-u.ac.jp (M.M.)
- 23 *Corresponding author

25

24 E-mail: ogata@naramed-u.ac.jp (Nahoko Ogata)

Abstract

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Retinal vein occlusion (RVO) is a major retinal disease accompanied by venous thrombosis. Although several studies have proposed an association between venous thrombosis and von Willebrand factor (VWF), the association between RVO and VWF remains unclear. We aimed to investigate the association between RVO and VWF and the alteration of VWF levels under the antivascular endothelial growth factor (VEGF) treatment. We enrolled 55 patients with RVO involved cystoid macular edema. They received intravitreal injection of anti-VEGF drugs, either ranibizumab or aflibercept. We examined the clinical data, measured plasma VWF: antigen (VWF: Ag) and plasma a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (ADAMTS13: AC) and analyzed them to identify variabilities during the treatment. At the baseline there was no significant difference between the RVO group and age-matched controls in both VWF: Ag and ADAMTS13: AC levels but ADAMTS13:AC was significantly lower in central RVO (CRVO) than in branch RVO (BRVO) (P = 0.015). In BRVO, the negative correlation was found between VWF: Ag and central choroidal thickness (CCT) (r = -0.51, P < 0.001). In BRVO after the anti-VEGF treatment, VWF: Aq

44 decreased significantly from 134% at the baseline to 109% at 1 day after (P = 0.002) and to 107% at 1 month after (P = 0.030). In contrast, ADAMTS13: AC 45 showed no significant difference during this period. In BRVO at 1 month after 46 treatment, we found a negative correlation between VWF: Ag and CCT (r = -0.47, P = 0.001). Our findings suggest an association between VWF and CCT 48 in patients with BRVO, thus the measurement of VWF may be useful for 49 evaluating the disease activity and prognosis. 50

47

Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Von Willebrand factor (VWF), a large glycoprotein synthesized and secreted from vascular endothelial cells, acts as bridging molecule which adheres platelets to the injured vessels and stabilizes coagulation factor VIII [1]. VWF is specifically cleaved by disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) [2]. The balance between VWF and ADAMTS13 maintains the hemostaticaly coagulative function of the whole body. The release of VWF is known to increase with endothelial cell damage and elevated plasma VWF levels are usually observed in patients with hypertension and atherosclerosis [3-5]. Karaca et al. reported an association between plasma VWF and the severity of hypertensive retinopathy [6]. In other ocular diseases, elevated plasma VWF antigen (VWF: Ag) has been reported in agerelated macular degeneration (AMD), and multimeric VWF has been found in pachychoroid neovasculopathy [7-9]. Several studies have also reported that increased plasma VWF levels are associated with thrombotic complications [10–12]. Interestingly, this association includes not only atherothrombotic diseases (such as myocardial infarction or ischemic stroke) but also venous thrombosis. Edvardsen et al. recently

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

suggested an association between VWF and venous thrombosis, such as deep vein thrombosis and pulmonary embolism [12]. Retinal vein occlusion (RVO) is a major retinal disease that causes retinal hemorrhage and severe vision loss [13,14]. Vision loss in RVO is mainly due to cystoid macular edema (CME). RVO is a multifactorial disease with several risk factors, including age, hypertension, arteriosclerosis, diabetes mellitus, dyslipidemia, high blood viscosity, and thrombosis [14,15]. RVO can be classified into two types: branch RVO (BRVO) and central RVO (CRVO). In BRVO, although partial retinal ischemia may occur, blood perfusion throughout the retina is generally maintained [16]. Alternatively, the entire retina can become severely ischemic in CRVO, which leads to severe vision loss and neovascular glaucoma [17]. Usually, CRVO has a worse prognosis than BRVO. In patients with RVO, it is important to understand the retinal circulatory status to control the disease. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs has been widely used for the treatment of RVO with CME. However, CME often recurs and requires additional injections. The systemic side effects of anti-

VEGF vitreous injection remain controversial. Several studies have reported

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

thromboembolic events, including myocardial infarction and ischemic stroke [18,19]. In addition, anti-VEGF antibodies are known to enter the systemic circulation, decrease VEGF levels and affect other cytokines in the plasma [20]. We have already demonstrated that VWF: Ag levels were decreased after intravitreal aflibercept injection in patients with AMD [8]. Although RVO is accompanied by venous thrombosis, few clinical studies have examined the association between VWF and RVO and these studies have reported different results. Thus, the levels of VWF in RVO remain controversial [21–23]. Furthermore, no study has investigated whether plasma VWF is influenced by anti-VEGF vitreous injection in patients with RVO. In this study, we aimed to investigate the involvement of VWF in the pathogenesis of RVO and its variability after anti-VEGF injection. **Methods** This prospective study was conducted at Nara Medical University Hospital, Kashihara City, Nara Prefecture, Japan, from June 2014 to March 2020. This study protocol was approved by the medical research ethics committee of Nara

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Medical University and followed the Declaration of Helsinki. We confirmed that all methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent for participation in the study. Fifty-five patients diagnosed as RVO with CME who were aged 51 to 91 years and age-matched control subjects (patients before cataract surgery) were enrolled in this study. Patients who had severe systemic complications or did not receive anti-VEGF drugs, that is selected other treatments, were excluded. RVO was diagnosed based on ophthalmological findings, slit lamp examination, fundus examination, optical coherence tomography, wide-angle fundus photography, and fluorescein angiography. We also examined best-corrected visual acuity (BCVA, LogMAR unit), central retinal thickness (CRT), and central choroidal thickness (CCT). The pathological classification (BRVO or CRVO) was judged independently by two researchers based on the examinations. All patients received intravitreal injections of anti-VEGF drugs, either ranibizumab (Lucentis; Novartis International AG, Basel, Switzerland) or aflibercept (Eylea; Bayer HealthCare Pharmaceuticals, Berlin, Germany) at a dose of 2.0 mg/0.05 mL. The drugs were selected by the attending physicians.

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

The intravitreal injection was approached 3.5–4.0 mm posterior to the corneal limbus. Whole blood was collected by venipuncture of the anterior arm into a tube containing 3.8% trisodium citrate (1:9). Blood samples were collected four times: before treatment (first visit), 1 day after treatment, 1 week after treatment, and 1 month after treatment. All plasma samples were stored at -80°C and thawed at 37°C prior to examination. We measured plasma VWF: Ag levels using sandwich enzyme-linked immunosorbent assay (ELISA), rabbit anti-human VWF polyclonal antiserum (DAKO, Glostrup, Denmark) [24], and plasma ADAMTS13 activity (ADAMTS13: AC) by chromogenic ADAMTS13 activity ELISA (Kainos, Tokyo, Japan) [25]. We defined the 100% reference value as the amount of VWF: Ag and ADAMTS13: AC in pooled normal plasma from 20 volunteers (10 men and 10 women) aged between 20 and 40 years. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [26]. We used t-tests to compare two continuous variables (such as age) and Fisher's exact tests to

compare the proportions of categorical variables (such as sex) between the groups. We also used the Friedman and Wilcoxon signed-rank tests to compare the four continuous variables (VWF: Ag). Correlations were evaluated using Pearson's correlation coefficient. The threshold for significance was set at P < 0.05.

Results

The characteristics of the patients with RVO and controls are summarized in Table 1. In patients with RVO, the median age was 73.0 years, and 33 (60%) were male. Twenty-seven (49%) patients had hypertension. There was no significant difference in VWF: Ag and ADAMTS13: AC between the RVO group and the controls (P = 0.70 and P = 0.22, respectively). We also examined the baseline characteristics of patients with RVO classified according to RVO type, BRVO and CRVO. Both CRT and CCT were significantly thicker in CRVO than in BRVO (P = 0.013 and 0.045, respectively). The number of dyslipidemia cases was also significantly higher in CRVO than in BRVO (P = 0.004). Although VWF: Ag showed no significant difference between the two groups (P = 0.18), ADAMTS13:AC was significantly lower in CRVO than in BRVO (P = 0.18).

0.015). In other categories, there were no significant differences between the two groups. We assessed the blood type because the blood O group had lower plasma VWF: Ag levels than the other groups [27]. There was no difference in the blood type between the two groups.

Table 1: Basic characteristics of RVO patients and control

	Total RVO	Control	P	BRVO	CRVO	P
	(n=55)	(n=96)	value	(n=43)	(n=12)	value
Age, median (IQR)	73.0 (65.0-79.0)	74.0 (69.0-80.0)	0.18†	73.0 (66.0-79.5)	72.0 (64.0-74.3)	0.33†
Sex (male), n (%)	33 (60)	52 (54)	0.50‡	23 (53)	10 (83)	0.10‡
BCVA, median (IQR),	0.40 (0.15-0.52)	_		0.30 (0.15-0.52)	0.40 (0.28-0.57)	0.19†
CRT (µm), median (IQR)	477 (357-614)	_		440 (343-586)	574 (491-747)	0.013†
CCT (µm), median (IQR)	238 (197-264)	_		235 (180-259)	257 (214-298)	0.045†
Hypertension, n (%)	27 (49)	_		20 (47)	7 (58)	0.53‡
Dyslipidemia, n (%)	13 (24)	_		6 (14)	7 (58)	0.004‡
Diabetes, n (%)	6 (11)	_		4 (9)	2 (17)	0.60‡
Cardiovascular disease, n (%)	8 (15)	_		6 (14)	2 (17)	1‡
VWF (%), median (IQR)	134 (92-173)	130 (109-167)	0.70†	139 (107-175)	92 (60-122)	0.18†
ADAMTS13 (%), median (IQR)	45 (33-61)	54 (45-63)	0.22†	51 (38-69)	34 (29-39)	0.015†
Blood Type, n (%)						
Type O	18 (33)	32 (33)	1‡	12 (28)	6 (50)	0.18‡
Type A	23 (42)	34 (35)	0.49‡	19 (44)	4 (33)	0.74‡
Type B	9 (16)	16 (17)	1‡	9 (21)	0 (0)	0.18‡
Type AB	5 (9)	14 (15)	0.45‡	3 (7)	2 (17)	0.30‡

RVO, retinal vein occlusion

IQR, interquartile range

BRVO, branch retinal vein occlusion

CRVO, central retinal vein occlusion

BCVA, best-corrected visual acuity (LogMAR unit) CRT, central retinal thickness CCT, central choroidal thickness VWF, Von Willebrand factor † t test ‡ fisher's exact test 180 181 182 183 184 185 186 187

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

Fig. 1 shows the correlation between VWF: Ag and each parameter at the baseline. In BRVO, there was a positive correlation between VWF: Ag and CRT (r = 0.30, P = 0.049). We also found a strong negative correlation between VWF: Ag and CCT (r = -0.51, P < 0.001). In CRVO, no correlations were found in any of the categories. Fig. 1. The correlation between VWF: Ag and parameters (BCVA, CRT, and **CCT) at the baseline.** In each graph, the horizontal axis presents the VWF: Ag (%). VWF: Ag, plasma VWF: antigen; BCVA, best-corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness. Table 2 shows the basic characteristics of patients with RVO classified according to the selected anti-VEGF drugs. We confirmed that there were no significant differences between the two groups.

Table 2: Basic characteristics of patients classified by anti VEGF drugs

		Aflibercept Ranibizumab		P
207		(n=28)	(n=27)	value
	Age, median (IQR)	74.0 (66.0-79.0)	72.0 (63.5-78.0)	0.78†
208	Sex (male), n (%)	15 (54)	18 (67)	0.41‡
	RVO type	21 / 7	22 / 5	0.75‡
09	(BRVO / CRVO)			
	BCVA, median (IQR)	0.22 (0.14-0.52)	0.39 (0.26-0.61)	0.17†
10	CRT (µm), (IQR)	456 (358-626)	481 (371-586)	1†
	CCT (µm), (IQR)	233 (199-257)	251 (187-278)	0.58†
11	VWF (%), median (IQR)	118 (82-164)	139 (111-183)	0.54†
	ADAMTS13 (%), median (IQR)	40 (31-53)	51 (34-69)	0.67†

212 IQR, interquartile range

206

216

217

BRVO, branch retinal vein occlusion

213 CRVO, central retinal vein occlusion

BCVA, best-corrected visual acuity (LogMAR unit)

 $_{214}$ CRT, central retinal thickness

CCT, central choroidal thickness

VWF, Von Willebrand factor

† t test ‡ Fisher's exact test

219

220

221

222

223

224

225

226

227

228

229

230

231

Table 3 shows the alterations of clinical data in patients with RVO by treatment. In total RVO, BCVA significantly improved from 0.40 at the baseline to 0.22 at 1 month after anti-VEGF treatment (P < 0.001). Both CRT and CCT were significantly thinner at 1 month after treatment (P < 0.001 and 0.001, respectively). In BRVO, BCVA also significantly improved from 0.35 at the baseline to 0.15 at 1 month after treatment (P < 0.001). Both CRT and CCT were significantly thinner at 1 month after treatment (P < 0.001 and P = 0.003, respectively). In CRVO, BCVA significantly improved from 0.40 at the baseline to 0.35 at 1 month after treatment (P = 0.004). CRT was significantly thinner at 1 month after treatment (P < 0.001), whereas there was no significant difference in CCT (P = 0.24).

Table 3: Alterations of clinical data in patients with RVO by treatments

	Total RVO (n=55)		<i>P</i> value	BRVO (n=43)		<i>P</i> value	CRVO (n=12)		<i>P</i> value
	Baseline	1 month		Baseline	1 month		Baseline	1 month	
BCVA, median	0.40	0.22	< 0.001†	0.35	0.15	< 0.001†	0.40	0.35	0.040†
(IQR)	(0.15-0.52)	(0.05-0.40)		(0.15-0.52)	(0.05-0.46)		(0.28-0.57)	(0.21-0.40)	
CRT(µm), median	477	224	< 0.001†	440	222	< 0.001†	574	239	<0.001†
(IQR)	(357-614)	(199-251)		(343-586)	(196-244)		(491-747)	(219-258)	
CCT (µm), median	238	215	0.001†	235	213	0.003†	257	242	0.24†
(IQR)	(197-264)	(174-270)		(180-259)	(160-267)		(214-298)	(204-290)	

IQR, interquartile range

BRVO, branch retinal vein occlusion

CRVO, central retinal vein occlusion

BCVA, best-corrected visual acuity (LogMAR unit)

CRT, central retinal thickness

CCT, central choroidal thickness

† paired t test

232

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

Fig. 2 shows the correlation between VWF: Ag and each parameter 1 month after anti-VEGF treatment. In BRVO, we found a negative correlation between VWF: Ag and CCT (r = -0.47, P = 0.001). In CRVO, no correlations were found in any of the categories. Fig. 2. The correlation between VWF: Ag and parameters (BCVA, CRT, and CCT) 1 month after anti-VEGF treatment. In each graph, the horizontal axis presents the VWF: Ag (%). VWF: Ag, plasma VWF: antigen; BCVA, bestcorrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness. Fig. 3 shows the time course of VWF: Ag in patients with total RVO, BRVO, and CRVO. In total RVO, VWF: Ag decreased significantly from 134% at the baseline to 104% at 1 day after treatment (P = 0.002). In BRVO, VWF: Ag also showed a significant reduction from 139% at baseline to 113% at 1 day after treatment (P = 0.002) and to 98% at 1 month after treatment (P = 0.030). However, in CRVO, VWF: Ag showed no significant difference during this period. ADAMTS13: AC showed no significant difference during the study

period in all categories. 252 253 Fig 3. Alterations of VWF: Ag after anti-VEGF treatment (⋅< 0.05, **< 0.01). 254 Each of the values above the graph presents the median with the interquartile 255 256 range.

Discussion

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

This study investigated the coagulation-related factors in patients with RVO at the baseline and their alterations during the treatment. According to our results, there was no significant difference in plasma VWF between the RVO and age-matched controls at the baseline. Several researchers have reported that plasma VWF increased not only in patients with hypertension and arteriosclerosis but also in healthy individuals with aging [28,29]. ADAMTS13:AC was significantly lower in CRVO than in BRVO at the baseline. Interestingly, the number of dyslipidemia cases was significantly higher in CRVO than in BRVO. ADAMTS13 is mainly synthesized in hepatic stellate cells [2]. Thus the liver cells in patients with dyslipidemia would be damaged by fat deposition, then production of ADAMTS13 could be decreased in patients with CRVO. Although it was not statistically significant, the VWF levels in BRVO were higher than those in CRVO. BRVO is accompanied by a thrombus at the arteriovenous crossing point where the retinal artery and vein share an outer sheath [30,31], therefore the arterial pressure directly cause thrombosis. Alternatively, CRVO is

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

accompanied by a thrombus in the central retinal vein where it passes through the lamina cribrosa within the optic nerve. A recent study focusing on BRVO and CRVO has shown that atherosclerosis is a more inducing factor for developing BRVO than that for CRVO [32]. High levels of plasma VWF in our study suggest the atherosclerosis in BRVO. We also compared VWF levels and each ophthalmologic parameters of RVO and found a significant negative correlation between VWF: Ag and CCT in BRVO at the baseline. Although studies examining the association between VWF and choroidal thickness are few, Gifford et al. reported an inverse association between choroidal thickness and VWF in patients with liver cirrhosis [33]. Many previous reports demonstrated that choroidal thickness in patients with RVO decreases after intravitreal injection of anti-VEGF drugs [34]. Sakanishi et al. reported that the recurrence of CME was significantly few in cases with choroidal thinning after treatment [35]. Thus, CCT may reflect the treatment effect and prognosis in RVO. Interestingly, a significant negative correlation between VWF: Ag and CCT was still observed 1 month after anti-VEGF injection in BRVO. Therefore, the measurement of VWF: Ag during the treatment may be useful in evaluating the disease activity of BRVO. VWF: Ag

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

also showed significant alterations under anti-VEGF treatment, especially in BRVO. Several researchers have previously proposed the association between VWF and VEGF [36,37]. VWF is secreted from endothelial-specific organelles, called Weibel palade bodies (WPBs) which widely distribute in the systemic vessels [2]. VEGF activates exocytosis of WPBs, resulting in the release of VWF [37,38] which activates VEGF-R2 signaling and may promote angiogenesis [39]. Although few studies have examined the association between anti-VEGF drugs and VWF, Pace et al. reported decreased VWF plasma levels after anti-VEGF treatment (bevacizumab) in recurrent glioma [40]. We also report the VWF reduction after anti-VEGF treatment in patients with BRVO. Thus, the alterations of VWF may reflect the therapeutic effect after anti-VEGF drug administration in BRVO. This study has some limitations. First, this was a cross-sectional study with a relatively small sample size. A larger number of patients will be required for more accurate analyses. Second, we only assessed patients who received anti-VEGF drugs. It might be necessary to compare VWF levels in patients with and without treatment at the same time course. However, it is difficult to analyze untreated patients through frequent medical visits. Finally, we did not evaluate

the long-term effects of anti-VEGF drugs for more than 1 month after intravitreal injection. A longer follow-up period is required to confirm these results. Conclusion In summary, we performed prospective analyses on VWF in patients with RVO during the treatment and found unique characteristics. Our findings suggest an association between VWF and CCT in BRVO, thus the measurement of VWF may be useful for evaluating the disease activity and prognosis. **Acknowledgements** The authors thank Hiroki Tsujinaka for his useful discussions and Editage (www.editage.com) for English language editing.

References

- 1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev
- 331 Biochem. 1998;67: 395-424. doi: 10.1146/annurev.biochem.67.1.395, PubMed
- 332 PMID: 9759493.

- 2. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the
- scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.
- 335 Blood. 2011;118: 3212-3221. doi: 10.1182/blood-2011-02-306597, PubMed
- 336 PMID: 21715306, PubMed Central PMCID: PMC3179391.
- 337 3. Blann AD, Nagvi T, Waite M, McCollum CN. Von Willebrand factor and
- endothelial damage in essential hypertension. J Hum Hypertens. 1993;7: 107-
- 339 111. PubMed PMID: 8510081.
- 4. Blann AD, McCollum CN. Von Willebrand factor, endothelial cell damage and
- 341 atherosclerosis. Eur J Vasc Surg. 1994;8: 10-15. doi: 10.1016/s0950-
- 342 821x(05)80112-4, PubMed PMID: 8307205.
- 5. Lip GY, Blann A. Von Willebrand factor: a marker of endothelial dysfunction
- in vascular disorders? Cardiovasc Res. 1997;34: 255-265. doi: 10.1016/s0008-
- 345 <u>6363(97)00039-4</u>, PubMed PMID: <u>9205537</u>.
- 6. Karaca M, Coban E, Ozdem S, Unal M, Salim O, Yucel O. The association

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

between endothelial dysfunction and hypertensive retinopathy in essential hypertension. Med Sci Monit. 2014;20: 78-82. Epub: 78-82. doi: 10.12659/MSM.889659, PubMed PMID: 24441931, PubMed Central PMCID: PMC3907530. 7. Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology. 2001;108: 705-710. doi: 10.1016/s0161-6420(00)00663-1, PubMed PMID: 11297487. 8. Yamashita M, Matsumoto M, Hayakawa M, Sakai K, Fujimura Y, Ogata N. Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration. Sci Rep.: 2018: 8(1):1491. doi: 10.1038/s41598-018-19473-0, PubMed PMID: 29367644, PubMed Central PMCID: PMC5784081. 9. Hirai H, Yamashita M, Matsumoto M, Hayakawa M, Sakai K, Ueda T, et al. Analysis focusing on plasma von Willebrand factor in pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep.: 2021: 11(1):19987. Epub: 20211007. doi: 10.1038/s41598-021-99557-6, PubMed

PMID: 34620972, PubMed Central PMCID: PMC8497477.

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

10. Buchtele N, Schwameis M, Gilbert JC, Schörgenhofer C, Jilma B. Targeting von Willebrand factor in ischaemic stroke: focus on clinical evidence. Thromb Haemost. 2018;118: 959-978. doi: 10.1055/s-0038-1648251, PubMed PMID: 29847840, PubMed Central PMCID: PMC6193403 established to discover and develop novel biotherapeutics targeting von Willebrand factor. Other authors declare no conflict of interest. 11. Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117: 1449-1459. doi: 10.1161/CIRCULATIONAHA.107.722827, PubMed PMID: 18347221. 12. Edvardsen MS, Hindberg K, Hansen ES, Morelli VM, Ueland T, Aukrust P, et al. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Adv. 2021;5: 224-232. doi: 10.1182/bloodadvances.2020003135, PubMed PMID: 33570640, PubMed Central PMCID: PMC7805310. 13. Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion. J Ophthalmol. 2017;2017: 4936924. doi: 10.1155/2017/4936924, PubMed PMID: 28386476, PubMed Central PMCID:

PMC5366235.

- 14. Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al.
- Prevalence and systemic risk factors for retinal vein occlusion in a general
- Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci. 2010;51:
- 387 3205-3209. doi: 10.1167/iovs.09-4453, PubMed PMID: 20071683.
- 15. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-
- analysis of published clinical data. J Ophthalmol. 2014;2014. Epub: 724780:
- 390 724780. doi: 10.1155/2014/724780, PubMed PMID: 25009743, PubMed Central
- 391 PMCID: PMC4070325.
- 16. Hamid S, Mirza SA, Shokh I. Branch retinal vein occlusion. J Ayub Med Coll
- 393 Abbottabad. 2008;20: 128-132. [Epub 2009/04/24]. PubMed PMID: 19385476.
- 17. Bradshaw SE, Gala S, Nanavaty M, Shah A, Mwamburi M, Kefalas P.
- 395 Systematic literature review of treatments for management of complications of
- ischemic central retinal vein occlusion. BMC Ophthalmol. 2016;16: 104. Epub:
- 397 104. doi: 10.1186/s12886-016-0282-5, PubMed PMID: 27401800, PubMed
- 398 Central PMCID: PMC4940864.
- 18. Falavarjani KG, Nguyen QD. Adverse events and complications associated
- with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond).

- 401 2013;27: 787-794. Epub: 787-794. doi: 10.1038/eye.2013.107, PubMed PMID:
- 402 23722722, PubMed Central PMCID: PMC3709385.
- 403 19. Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk.
- 404 Intern Emerg Med. 2020;15: 199-210. Epub: 199-210. doi: 10.1007/s11739-
- 405 019-02253-7, PubMed PMID: 31848994.
- 406 20. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T.
- 407 Plasma levels of vascular endothelial growth factor and pigment epithelium-
- 408 derived factor before and after intravitreal injection of bevacizumab. Br J
- 409 Ophthalmol. 2010;94(9):1215-8. Epub: 20100610. doi:
- 410 10.1136/bjo.2008.156810, PubMed PMID: 20538658.
- 411 21. Cortinovis A, Crippa A, Crippa M. Factor VIII/Ag (von Willebrand) and
- 412 protein C. Erythrocyte deformability and aggregability. The risk parameters of
- retinal vein occlusion. Minerva Med. 1994;85: 211-219. [Epub 1994/05/01]. 413
- 414 PubMed PMID: 8028749.
- 22. Lip PL, Blann AD, Jones AF, Lip GY. Abnormalities in haemorheological 415
- 416 factors and lipoprotein (a) in retinal vascular occlusion: implications for
- 417 increased vascular risk. Eye (Lond). 1998;12: 245-251. doi:
- 418 10.1038/eye.1998.58, PubMed PMID: 9683948.


- 419 23. Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, et al. Plasma
- 420 homocysteine, methylene tetrahydrofolate reductase C677T and factor II
- G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. 421
- 422 Br J Ophthalmol. 2001;85: 1313-1315. doi: 10.1136/bjo.85.11.1313, PubMed
- 423 PMID: 11673296, PubMed Central PMCID: PMC1723784.
- 424 24. Matsumoto M, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, et al.
- 425 Platelets treated with ticlopidine are less reactive to unusually large von
- 426 Willebrand factor multimers than are those treated with aspirin under high shear
- 427 stress. Pathophysiol Haemost Thromb. 2005;34: 35-40. doi:
- 428 10.1159/000088546, PubMed PMID: 16293984.
- 429 25. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel
- 430 monoclonal antibody-based enzyme immunoassay for determining plasma
- levels of ADAMTS13 activity. Transfusion. 2006;46: 1444-1452. doi: 431
- 432 10.1111/j.1537-2995.2006.00914.x, PubMed PMID: 16934083.
- 433 26. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for
- 434 medical statistics. Bone Marrow Transplant. 2013;48: 452-458. doi:
- 435 10.1038/bmt.2012.244, PubMed PMID: 23208313, PubMed Central PMCID:
- PMC3590441. 436

- 27. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E,
- et al. A shorter von Willebrand factor survival in O blood group subjects explains
- how ABO determinants influence plasma von Willebrand factor. Blood.
- 2008;111: 3540-3545. doi: 10.1182/blood-2007-11-122945, PubMed PMID:
- 441 **18245665**.
- 28. Alavi P, Rathod AM, Jahroudi N. Age-associated increase in
- thrombogenicity and its correlation with von Willebrand factor. J Clin Med.
- 2021;10. Epub: 20210916. doi: <u>10.3390/jcm10184190</u>, PubMed PMID:
- 445 34575297, PubMed Central PMCID: PMC8472522.
- 29. Biguzzi E, Castelli F, Lijfering WM, Cannegieter SC, Eikenboom J,
- Rosendaal FR, et al. Rise of levels of von Willebrand factor and factor VIII with
- age: role of genetic and acquired risk factors. Thromb Res. 2021;197: 172-178.
- 449 Epub: 172–178. doi: 10.1016/j.thromres.2020.11.016, PubMed PMID:
- 450 **33221577**.
- 451 30. Hawkins WR. Anatomy of arteriovenous crossings in branch retinal vein
- occlusion. Am J Ophthalmol. 1990;110: 97-98. doi: 10.1016/s0002-
- 453 <u>9394(14)76953-3</u>, PubMed PMID: <u>2368833</u>.
- 454 31. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D.


- Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol.
- 456 1982;100: 1132-1140. doi: 10.1001/archopht.1982.01030040110020, PubMed
- 457 PMID: <u>6178389</u>.
- 32. Lyu M, Lee Y, Kim BS, Kim HJ, Hong R, Shin YU, et al. Clinical significance
- of subclinical atherosclerosis in retinal vein occlusion. Sci Rep.: 2021:
- 460 11(1):11905. Epub: 20210607. doi: 10.1038/s41598-021-91401-1, PubMed
- 461 PMID: 34099806, PubMed Central PMCID: PMC8184809.
- 33. Gifford FJ, Moroni F, Farrah TE, Hetherington K, MacGillivray TJ, Hayes
- PC, et al. The eye as a non-invasive window to the microcirculation in liver
- cirrhosis: A prospective pilot study. J Clin Med. 2020;9. Epub: 20201017. doi:
- 465 10.3390/jcm9103332, PubMed PMID: 33080821, PubMed Central PMCID:
- 466 PMC7603064.
- 34. Kim KH, Lee DH, Lee JJ, Park SW, Byon IS, Lee JE. Regional choroidal
- 468 thickness changes in branch retinal vein occlusion with macular edema.
- 469 Ophthalmologica. 2015;234: 109-118. Epub: 109–118. doi: 10.1159/000437276,
- 470 PubMed PMID: 26305536.
- 35. Sakanishi Y, Morita S, Mashimo K, Tamaki K, Ebihara N. Subfoveal
- 472 choroidal thickness and treatment outcomes of intravitreal Aflibercept for branch

- 473 retinal vein occlusion. Life (Basel). 2021;11. Epub: 20210617. doi:
- 474 10.3390/life11060572, PubMed PMID: 34204557, PubMed Central PMCID:
- PMC8235093. 475
- 476 36. Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ,
- 477 et al. The heparin binding domain of von Willebrand factor binds to growth
- factors and promotes angiogenesis in wound healing. Blood. 2019;133: 2559-478
- 479 2569. Epub: 2559–2569. doi: 10.1182/blood.2019000510, PubMed PMID:
- 480 30975637, PubMed Central PMCID: PMC6566593.
- 481 37. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and
- 482 plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc
- 483 Biol. 2006;26: 1002-1007. doi: 10.1161/01.ATV.0000209501.56852.6c, PubMed
- 484 PMID: 16469951.
- 38. Randi AM. Endothelial dysfunction in von Willebrand disease: angiogenesis 485
- 486 and angiodysplasia. Thromb Res. 2016;141;Suppl 2: S55-S58. doi:
- 10.1016/S0049-3848(16)30366-8, PubMed PMID: 27207426. 487
- 488 39. Mojzisch A, Brehm MA. The manifold cellular functions of von Willebrand
- 489 factor. Cells. 2021;10. Epub: 20210908. doi: 10.3390/cells10092351, PubMed
- 490 PMID: 34572000, PubMed Central PMCID: PMC8466076.


- 40. Pace A, Mandoj C, Antenucci A, Villani V, Sperduti I, Casini B, et al. A 491
- predictive value of von Willebrand factor for early response to bevacizumab 492
- 493 therapy in recurrent glioma. J Neurooncol. 2018;138: 527-535. doi:
- 494 10.1007/s11060-018-2820-x, PubMed PMID: 29594657.



Figure



Figure



Figure